Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome

BACKGROUND: The incidence of alloimmunisation in myelodysplastic syndromes (MDS) during the era of supportive treatment ranges from 9 to 56%. However, it is unknown if the widespread use of hypomethylating agents has changed the risk of immunisation. The aim of this study is to evaluate the impact o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Transfus
Autors principals: Ortiz, Sebastián, Orero, Maria T., Javier, Karla, Villegas, Carolina, Luna, Irene, Pérez, Pedro, Roig, Mónica, López, María, Costa, Sofía, Carbonell, Félix, Collado, Rosa, Ivars, David, Linares, Mariano
Format: Artigo
Idioma:Inglês
Publicat: Edizioni SIMTI - SIMTI Servizi Srl 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5589710/
https://ncbi.nlm.nih.gov/pubmed/27416573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2450/2016.0012-16
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars